# Kodiak Sciences Inc.: overview KOD · Nasdaq · CIK 1468748 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/kod.md) · [Financials](/companies/kod/financials.md) · [Filings](/companies/kod/filings.md) · [Insiders](/companies/kod/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.84)](/filings/0001193125-25-280183.md) | not reported | [(1.09)](/filings/0001193125-26-211951.md) | [(1.03)](/filings/0001193125-26-349251.md) | [(1.16)](/filings/0001193125-25-280183.md) | not reported | [(0.94)](/filings/0001193125-26-211951.md) | [(1.05)](/filings/0001193125-26-349251.md) | | Free cash flow | $m | [(21.3) d](/filings/0001193125-25-280183.md) | [(30.2) d](/filings/0001193125-26-134887.md) | [(29.3)](/filings/0001193125-26-211951.md) | [(34.8) d](/filings/0001193125-26-349251.md) | [(32.9) d](/filings/0001193125-25-280183.md) | [(39.4) d](/filings/0001193125-26-134887.md) | [(41.0)](/filings/0001193125-26-211951.md) | [(46.6) d](/filings/0001193125-26-349251.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(5.16)](/filings/0000950170-24-038025.md) | [(6.39)](/filings/0000950170-25-046098.md) | [(4.97)](/filings/0001193125-26-134887.md) | [(3.35)](/filings/0001193125-26-134887.md) | [(4.32)](/filings/0001193125-26-134887.md) | | Free cash flow | $m | [(199)](/filings/0000950170-24-038025.md) | [(243)](/filings/0000950170-25-046098.md) | [(196)](/filings/0001193125-26-134887.md) | [(118)](/filings/0001193125-26-134887.md) | [(137)](/filings/0001193125-26-134887.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/kod/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-21 | [Borgeson John A.](/insiders/1754045.md) | Chief Financial Officer, Officer | Sale (S) | 100 | $94.91 | $9.5k | [Form 4](/filings/0001754045-26-000010.md) | | 2026-10-21 | [Borgeson John A.](/insiders/1754045.md) | Chief Financial Officer, Officer | Sale (S) | 2,000 | $93.71 | $187.4k | [Form 4](/filings/0001754045-26-000010.md) | | 2026-10-21 | [Borgeson John A.](/insiders/1754045.md) | Chief Financial Officer, Officer | Sale (S) | 2,000 | $92.66 | $185.3k | [Form 4](/filings/0001754045-26-000010.md) | | 2026-10-21 | [Borgeson John A.](/insiders/1754045.md) | Chief Financial Officer, Officer | Sale (S) | 2,985 | $91.76 | $273.9k | [Form 4](/filings/0001754045-26-000010.md) | | 2026-10-21 | [Borgeson John A.](/insiders/1754045.md) | Chief Financial Officer, Officer | Sale (S) | 5,101 | $90.98 | $464.1k | [Form 4](/filings/0001754045-26-000010.md) | | 2026-10-21 | [Borgeson John A.](/insiders/1754045.md) | Chief Financial Officer, Officer | Sale (S) | 7,623 | $89.74 | $684.1k | [Form 4](/filings/0001754045-26-000010.md) | | 2026-10-21 | [Borgeson John A.](/insiders/1754045.md) | Chief Financial Officer, Officer | Sale (S) | 1,677 | $89.20 | $149.6k | [Form 4](/filings/0001754045-26-000010.md) | | 2026-10-21 | [Borgeson John A.](/insiders/1754045.md) | Chief Financial Officer, Officer | Sale (S) | 8,514 | $87.67 | $746.4k | [Form 4](/filings/0001754045-26-000010.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $776.1m | 19,919,186 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $161.1m | 4,135,355 | | Added +200,053 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $94.3m | 2,419,417 | | Added +168,497 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $90.2m | 2,316,014 | | Added +627,011 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $70.3m | 1,804,632 | | Added +87,556 | | [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $69.6m | 1,787,318 | | Reduced −31,347 | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $59.5m | 1,526,006 | | Not compared | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $58.0m | 1,487,934 | | Unchanged | | [Boxer Capital Management, LLC](/funds/2018299.md) | 2026-06-30 | $57.6m | 1,477,600 | | Added +116,600 | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $56.3m | 1,445,538 | | Unchanged | ## Recent filings [All 420 filings](/companies/kod/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-30 | 16:39 ET | [SCHEDULE 13D/A](/filings/0001104659-26-112371.md) | Ownership report, active investor, amended | 0001104659-26-112371 | | 2026-09-28 | 08:53 ET | [8-K](/filings/0001193125-26-403481.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-403481 | | 2026-08-13 | 16:17 ET | [10-Q](/filings/0001193125-26-349251.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349251 | | 2026-08-13 | 16:00 ET | [8-K](/filings/0001193125-26-349107.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349107 | | 2026-06-04 | 17:22 ET | [8-K](/filings/0001193125-26-257766.md) | 5.07 Shareholder vote results | 0001193125-26-257766 | | 2026-05-07 | 16:15 ET | [10-Q](/filings/0001193125-26-211951.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211951 | | 2026-05-07 | 16:00 ET | [8-K](/filings/0001193125-26-211811.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211811 | | 2026-04-22 | 16:14 ET | [DEF 14A](/filings/0001193125-26-170429.md) | Proxy statement, period 2026-06-02 | 0001193125-26-170429 | | 2026-03-31 | 17:02 ET | [10-K](/filings/0001193125-26-134887.md) | Annual report, period 2025-12-31 | 0001193125-26-134887 | | 2026-03-31 | 16:54 ET | [8-K](/filings/0001193125-26-134854.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-134854 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-134887.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1468748 - Tickers: KOD - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 17:02 ET. No prices; not investment advice.